KALAMAZOO, Mich. and PALO ALTO, Calif., Aug. 30, 2017 /PRNewswire/ -- Ablative Solutions, Inc. (ASI), a venture-backed, privately held company headquartered in Kalamazoo, MI, with offices in Palo Alto, CA, announced today that they will be presenting at the annual Baird Global Healthcare Conference in New York City, September 6-7, 2017. The ASI presentation will be at 10:15 AM on September 6, 2017 at the InterContinental Hotel, New York Barclay.
Ablative Solutions' CEO Dr. Tim Fischell commented, "The Baird Global Healthcare Conference is a premier gathering of innovative companies and world-class investors. In light of potentially positive shifts in market dynamics, we believe this is a perfect venue to showcase our company as well as provide important clinical and regulatory updates."
Ablative Solutions, Inc. (ASI) has developed the Peregrine System™ Infusion Catheter that is delivered using minimally invasive technique through a small access site in the femoral artery. In the renal artery, a proprietary deployment system centers the device and, using microneedles, accesses the area outside the renal artery. In the U.S., the Peregrine Catheter has been 510(k) cleared by the U.S. Food and Drug Administration (FDA) for the infusion of diagnostic and therapeutic agents into the perivascular area. The Peregrine catheter has also received CE mark for the infusion of a neurolytic agent (such as alcohol) in the perivascular space to achieve a reduction in systemic blood pressure in hypertensive patients.
The Peregrine System™ is currently being studied in a European post-market open-label clinical trial using ethanol as a neurolytic agent to disrupt the sympathetic nerves located in the outer region of the renal arteries, referred to as renal denervation (RDN). Renal Denervation may have therapeutic implications for a number of diseases and conditions, including hypertension. In September 2016, ASI announced that the FDA has allowed the company's Investigational New Drug (IND) application for the Peregrine System™ Kit, for catheter-based renal denervation with targeted delivery of ethanol in the perivascular space. Under the IND, ASI plans to conduct a multi-center, double-blind, randomized, sham-controlled trial for the treatment of refractory hypertension.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities in an ASI stock offering. There will not be any sale of these securities in any state or jurisdiction in which such offering, sale or solicitation would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Statements made in this press release that look forward in time or that express beliefs, expectations or hopes regarding future occurrences or anticipated outcomes or benefits are forward-looking statements. A number of risks and uncertainties, such as risks related to product development and commercialization efforts, results of clinical trials, ultimate clinical outcomes and benefit of ASI's products to patients, market and physician acceptance of ASI's products, intellectual property protection and competitive product offerings, could cause actual events to differ from the expectations indicated in these forward-looking statements. You are cautioned not to put any undue reliance on any forward-looking statement. This press release is neither an offer to sell nor a solicitation of an offer to purchase any particular securities. Any such offer or solicitation will be made only pursuant to definitive legal agreements prepared specifically for such purpose. ASI does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE Ablative Solutions, Inc.